Dual targeting of PI3K and BCL‐2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma

Despite significant efficacy of ibrutinib therapy in mantle cell lymphoma (MCL), about one‐third of MCL patients will display primary resistance. In time, secondary resistance occurs almost universally with an unlikely response to salvage chemotherapy afterwards. While intense efforts are being dire...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Haige, Huang, Shengjian, Liu, Yang, Chen, Zhihong, Wang, Michael, Jiang, Vivian Changying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097828/
https://www.ncbi.nlm.nih.gov/pubmed/35352453
http://dx.doi.org/10.1111/jcmm.17297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097828/
https://www.ncbi.nlm.nih.gov/pubmed/35352453
http://dx.doi.org/10.1111/jcmm.17297

Ejemplares similares